Abstract BACKGROUND With the antiangiogenic metronomic MEMMAT combinatorial regimen, we could achieve sustained responses in a quarter of the patients with previously irradiated recurrent medulloblastoma. There are currently no molecular biomarkers predicting response to MEMMAT treatment for recurrent medulloblastoma. Lipid mediators, including classical arachidonic acid-derived eicosanoids and docosanoids, are locally acting bioactive signaling lipids that regulate a diverse set of homeostatic and inflammatory processes. Before initiation of MEMMAT treatment for relapsed medulloblastoma, we examined the bioactive lipid mediator profile in the cerebrospinal fluid (CSF) of patients and compared it with samples from patients with different neurological disorders, but without cancer. METHODS We analyzed CSF samples from 23 patients with relapsed MBL before initiation of MEMMAT treatment and from 12 controls. Lipid mediators were enriched via solid phase extraction and analyzed using liquid chromatography coupled to a high resolution orbitrap Exploris 480 mass spectrometer. RESULTS Mass spectrometry-based untargeted oxylipin analysis led to the identification of 98 lipid mediators. Several molecules were downregulated in medulloblastoma samples versus control, such as lipoxin A4 and 14(15)-DiHETE. Non-responders had lower levels of these molecules than responders. Glycodeoxycholic acid and deoxycholic acid were up-regulated in medulloblastoma patients, again with higher levels in non-responders. Remarkably, the docosahexaenoic acid (DHA)-derived 22-HDoHE was specifically identified in the CSF samples of medulloblastoma patients but not in control samples. CONCLUSION An oxylipin pattern in CSF might serve as a predictive biomarker signature for response in patients with recurrent medulloblastoma treated with the antiangiogenic metronomic MEMMAT regimen. Our findings advocate for the prospective assessment of CSF-derived lipid markers in future trials for recurrent medulloblastoma.